.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,247,438

« Back to Dashboard

Details for Patent: 8,247,438

Title:Methods for treating schizophrenia
Abstract: Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiaz- olidinyl}carbonylmethyl)ureido]phenyl}propionic acid and its physiological acceptable salts.
Inventor(s): Elkashef; Ahmed (Dunn Loring, VA)
Assignee: Neuropill, Inc. (Dunn Loring, VA)
Filing Date:Jun 10, 2008
Application Number:12/136,099
Claims:1. A method for treating schizophrenia comprising the administration of a compound of formula (I) ##STR00002## or a physiologically acceptable salt thereof to a human diagnosed as having schizophrenia, the compound being administered in an amount effective to treat at least one symptom of schizophrenia; wherein the at least one symptom of schizophrenia comprises hallucinations, delusions, anhedonia, poverty of speech, cognitive impairment, or a combination thereof.

2. The method of claim 1 wherein the compound of formula (I) or the physiologically acceptable salt thereof is administered orally.

3. The method of claim 1 wherein a capsule containing the compound of formula (I) is orally administered.

4. The method of claim 1 wherein a tablet containing the compound of formula (I) is orally administered.

5. The method of claim 2 wherein an aqueous solution containing the compound of formula (I) is orally administered.

6. The method of claim 2 wherein an aqueous suspension containing the compound of formula (I) is orally administered.

7. The method of claim 1 wherein the physiologically acceptable salt thereof is alkali metal, alkaline earth or ammonium salt.

8. The method of claim 1 wherein the effective amount is 200 to 1600 mg of the compound of formula (I).

9. The method of claim 1 wherein the compound of formula (I) or the physiologically acceptable salt thereof is administered topically.

10. The method of claim 1 wherein a transdermal patch containing the compound of formula (I) is topically administered.

11. A pharmaceutical composition in unit dosage form for treating schizophrenia comprising per dosage unit 800 to 1600 mg of a physiologically acceptable salt of a compound of formula (I) ##STR00003## with a pharmaceutically acceptable carrier in solid or liquid form.

12. A method for decreasing dopamine levels in basal ganglia comprising administrating a compound of formula (I) ##STR00004## or physiologically acceptable salt thereof to a human diagnosed as having schizophrenia, the compound being administered in an amount effective to decrease dopamine levels in basal ganglia of the human.

13. The method of claim 12 wherein the compound of formula (I) or the physiologically acceptable salt thereof is administered orally.

14. The method of claim 13 wherein a capsule containing the compound of formula (I) is orally administered.

15. The method of claim 13 wherein a tablet containing the compound of formula (I) is orally administered.

16. The method of claim 13 wherein an aqueous solution containing the compound of formula (I) is orally administered.

17. The method of claim 13 wherein an aqueous suspension containing the compound of formula (I) is orally administered.

18. The method of claim 13 wherein the physiologically acceptable salt thereof is alkali metal, alkaline earth or ammonium salt.

19. The method of claim 13 wherein the effective amount is 200 to 1600 mg of the compound of formula (I).

20. The method of claim 1, further comprising first diagnosing the human with schizophrenia before administration of the compound of formula (I) or the physiological acceptable salt thereof.

21. The method of claim 1, further comprising first identifying at least one symptom of schizophrenia in the human before administration of the compound of formula (I) or the physiological acceptable salt thereof.

22. The method of claim 21, wherein the at least one symptom of schizophrenia comprises hallucinations, delusions, anhedonia, poverty of speech, cognitive impairment, or a combination thereof.

23. The method of claim 12, further comprising first diagnosing the human with schizophrenia before administering the compound of formula (I) or the physiological acceptable salt thereof.

24. The method of claim 12, further comprising first identifying at least one symptom of schizophrenia in the human before administering the compound of formula (I) or the physiological acceptable salt thereof.

25. The method of claim 24, wherein the at least one symptom of schizophrenia comprises hallucinations, delusions, anhedonia, poverty of speech, cognitive impairment, or a combination thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc